Filing Flows › Arcturus Therapeutics Holdings (ARCT) › Grant revenue
Arcturus Therapeutics Holdings (ARCT) Grant revenue by quarter
Arcturus Therapeutics Holdings' Grant revenue was $1.4M in Q3 2026 (third quarter 2026), -30% from Q2 2026. Over the last 7 quarters it ranged from $1.4M (Q3 2026) to $4.1M (Q4 2025).
| Quarter | Grant revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.4M | -30% | -52% |
| Q2 2026 | $2.1M | +43% | -45% |
| Q1 2026 | $1.5M | -65% | -63% |
| Q4 2025 | $4.1M | +37% | — |
| Q3 2025 | $3.0M | -21% | — |
| Q2 2025 | $3.8M | -3% | — |
| Q1 2025 | $3.9M | — | — |
Q3 2026 at a glance
Arcturus Therapeutics Holdings, Q3 2026: revenue $18.3M (+7% year over year), operating margin -50.2%, net loss $7.4M, operating cash flow −$6.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Arcturus Therapeutics Holdings' Grant revenue?
Arcturus Therapeutics Holdings' Grant revenue was $1.4M in Q3 2026 (third quarter 2026), -30% from Q2 2026.
How has Arcturus Therapeutics Holdings' Grant revenue changed?
Over the last 7 quarters it ranged from $1.4M (Q3 2026) to $4.1M (Q4 2025).
Q3 2026 results → · How Arcturus Therapeutics Holdings makes money →